Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Strasbaugh (STRB)
|
Add to portfolio |
|
|
Price: |
$0.01
| | Metrics |
OS: |
14.2
|
M
| |
|
|
Market cap: |
$129.2
|
k
| |
|
|
Net cash:
|
$1.1
|
M
| |
$0.08
|
per share
|
EV:
|
|
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Mar-31-05 | Mar-31-04 | Mar-31-03 | Mar-31-02 | Mar-31-01 |
Revenues | 12.9 | 9.6 | 19.5 | 20.9 | 29.9 | 49.4 | 57.1 | 85.1 |
Revenue growth | 34.7% | -51.1% | | -30.0% | -39.4% | -13.4% | -32.9% | 76.4% |
Cost of goods sold | 8.5 | 7.1 | 11.4 | 15.0 | 22.2 | 39.1 | 51.8 | 77.5 |
Gross profit | 4.4 | 2.4 | 8.1 | 5.9 | 7.8 | 10.3 | 5.2 | 7.6 |
Gross margin | 34.4% | 25.6% | 41.6% | 28.3% | 25.9% | 20.9% | 9.1% | 8.9% |
Selling, general and administrative | 3.9 | 4.4 | 6.0 | 6.1 | 8.2 | 8.7 | 9.6 | 11.8 |
Research and development | 3.6 | 3.0 | 2.6 | 6.0 | 9.3 | 10.8 | 9.2 | 10.2 |
EBITA | -3.0 | -4.9 | -0.4 | -7.7 | -17.4 | -13.3 | -24.6 | -15.7 |
EBITA margin | -23.5% | -51.7% | -2.2% | -36.8% | -58.3% | -27.0% | -43.1% | -18.5% |
Amortization of intangibles | | | | | 0.3 | 0.2 | | |
EBIT | -3.0 | -4.9 | -0.4 | -7.7 | -17.7 | -13.6 | -24.6 | -15.7 |
EBIT margin | -23.5% | -51.7% | -2.2% | -36.8% | -59.1% | -27.4% | -43.1% | -18.5% |
Pre-tax income | -0.7 | -4.5 | -0.8 | 19.4 | -16.0 | -16.9 | -22.8 | -10.5 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | -0.2 | 0.1 |
Tax rate | 1.7% | 0.0% | | 1.1% | 0.0% | | 0.8% | |
Net income | -0.7 | -4.5 | -0.8 | 19.1 | -16.0 | -17.0 | -22.6 | -10.6 |
Net margin | -5.3% | -47.2% | -4.0% | 91.4% | -53.4% | -34.5% | -39.6% | -12.5% |
|
Diluted EPS | ($47.51) | ($0.32) | ($0.04) | $1.47 | ($1.28) | ($1.39) | ($1.87) | ($0.94) |
Shares outstanding (diluted) | 0.0 | 14.2 | 19.8 | 13.0 | 12.5 | 12.2 | 12.1 | 11.3 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|